The French government announced the approval of seven new industrial investment projects under the France 2030 initiative aimed at regaining the country’s pharmaceutical sovereignty. These projects, part of a larger scheme to relocate the production of essential medicines, will receive nearly 50 million euros in public support, prompting roughly 300 million euros in total investments. Key companies involved include Delpharm, Benta Lyon, and Ipsophene, with efforts focused on increasing production of vital medications like paracetamol and anti-epileptics.